Back to Authors

Uy, Geoffrey L.

https://orcid.org/0000-0002-7809-0996

Mayo Clinic

Washington University in St. Louis

Citations 65

Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).
Ritchie, Ellen K. , Sanford, Ben L. , Marcucci, Guido , Zhao, Weiqiang , Geyer, Susan M. , Powell, Bayard L., Baer, Maria R. , Cohen, Harvey Jay, Stone, Richard M. , Klepin, Heidi D. , Ballman, Karla V. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey L.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7102-7102

10.1200/jco.2014.32.15_suppl.7102 Get It

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia
Ngankeu, Apollinaire, Ranganathan, Parvathi , Havelange, Violaine , Volinia, Stefano , Powell, Bayard L., Kolitz, Jonathan E. , Uy, Geoffrey L. , Stone, Richard M. , Bloomfield, Clara D. , Garzon, Ramiro , Nicolet, Deedra , Kornblau, Steven M. , Andreeff, Michael , Croce, Carlo Maria , Uy, Geoffrey

Oncotarget | December 12, 2017 | Volume: 9 | Issue: 4 | Pages: 4354-4365

10.18632/oncotarget.23150 Get It

Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
Walter, Roland B. , Michaelis, Laura C. , Uy, Geoffrey L. , Radich, Jerald P. , Little, Richard F. , Hita, Sandi, Saini, Lalit , Foran, James M. , Gerds, Aaron T. , Couban, Stephen, Litzow, Mark R. , Stone, Richard M. , Little, Richard F , Gerds, Aaron T , Lancet, Jeffrey E , Walter, Roland B , Othus, Megan , Klepin, Heidi D. , Hay, Annette E. , Assouline, Sarit E. , Lancet, Jeffrey E. , Erba, Harry Paul , Uy, Geoffrey

American Journal of Hematology | November 22, 2017 | Volume: 93 | Issue: 2 | Pages: No page available

10.1002/ajh.24980 Get It

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina, Marcucci, Guido , Zhao, Weiqiang , Baer, Maria R. , Powell, Bayard L., Westervelt, Peter, DeAngelo, Daniel J. , Sanford, Ben L. , Blum, William , Bloomfield, Clara D. , Stone, Richard M. , Levis, Mark J. , Klepin, Heidi D. , Stock, Wendy , Larson, Richard A. , Uy, Geoffrey , Deangelo, D. J.

Blood Advances | January 25, 2017 | Volume: 1 | Issue: 5 | Pages: 331-340

10.1182/bloodadvances.2016003053 Get It

Key Points The addition of sorafenib to chemotherapy for older adults with FLT3-ITD mutated AML is safe and may improve overall survival.
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis
Deol, Abhinav , Sengsayadeth, Salyka, Ahn, Kwang Woo , Wang, Hailin , Aljurf, Mahmoud , Antin, Joseph H. , Cahn, Jean‐Yves , Camitta, Bruce, Chen, Yi‐Bin , Ganguly, Siddhartha , Inamoto, Yoshihiro , Jagasia, Madan , Kamble, Rammurti T., Koreth, John , Litzow, Mark R. , Marks, David I. , Olsson, Richard F. , Rowe, Jacob M. , Saad, Ayman , Sabloff, Mitchell , Schouten, Harry C. , Shea, Thomas C., Soiffer, Robert J. , Uy, Geoffrey L. , Waller, Edmund K. , Wiernik, Peter H. , Wirk, Baldeep , Woolfrey, Ann E. , Bunjes, Donald , Weisdorf, Dan, Khoury, H. Jean , Saber, Wael , Weisdorf, Daniel J. , Battiwalla, Minoo , Bornhäuser, Martin , Camitta, Bruce M., Cutler, Corey S. , Gale, Robert Peter , Hamadani, Mehdi , Lazarus, Hillard M. , Liesveld, Jane L. , Nishihori, Taiga , Reshef, Ran , Devine, Steven M. , Lima, Marcos de , Sandmaier, Brenda M , Saad, Ayman , Olsson, Richard F , Waller, Edmund K , Weisdorf, Dan , Uy, Geoffrey , Sabloff, Mitchell

Cancer | June 17, 2016 | Volume: 122 | Issue: 19 | Pages: 3005-3014

10.1002/cncr.30140 Get It

BACKGROUNDPatients with FMS like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT).METHODSData from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes.RESULTSIn total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild‐type (WT) group (38% [95% confidence interval (CI), 30%‐45%] vs 28% [95% CI, 24%‐33%]; P = .04; relative risk, 1.60 [95% CI, 1.15‐2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia‐free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3‐year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%‐57%; WT group: 55%, 95% CI, 50%‐60%; P = .20).CONCLUSIONSThe current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long‐term survivors. Cancer 2016;122:3005‐3014. © 2016 American Cancer Society.